AB0688

NEOPLASTIC RISK IN SYSTEMIC SCLEROSIS: A MONOCENTRIC STUDY

Katia Stefanantoni, Natalia Di Tommaso, Nicoletta Iannace, Iliana Sciarra, Carlotta Angelelli, Elena Marafioti, Greta Pellegrino, Massimiliano Vasile, Guido Valesini, Valeria Ricciari. *Sapienza Università di Roma, Medicina Interna e Specialità Mediche – Reumatologia, Rome, Italy*

Background: an increased risk of malignancies (1.5-5 times) was found in Systemic Sclerosis (SSc). Well recognized risk factors are the diffuse form, advanced age and (1), more recently, the positivity for anti-RNA Polymerase III antibodies (aRNAP3) has assumed considerable importance (2).

Objectives: the aim of this study was to evaluate the frequency of neoplasms and precancerous conditions, as well as the main risk factors, in our cohort of patients with SSc.

Methods: we enrolled 312 consecutive patients (288/92% females and 24/8% males, mean age 62.3 years, average disease duration 108 months) afferent at our department from 2000 to 2018, with a diagnosis of SSc confirmed according to the 2013 ACR/EULAR criteria (3). All patients underwent clinical, instrumental and laboratory evaluation. In 93 patients, negative for anti-topoisomerase I antibodies (aSci70) and anti-centromere antibodies (ACA), the presence of aRNAP3 antibodies was evaluated by an ELISA method (QUANTA Lite™ RNA Pol III).

Results: we found a limited form of disease in 229 patients (73.4%) and a diffuse form in 83 (26.6%). Eighty eight (28.2%) patients were positive for aSci70, 112 (35.9%) for ACA and 17 (5.4%) for aRNAP3. In the whole group, 44 (14%) patients had a positive familiar history for neoplasm while 105 (33.65%) had a history of neoplasms and/or precancerous conditions. Among these 105 cases, 44 (41.9%) were malignant, 50 (47.6%) benign and 11 (10.5%) had precancerous conditions. The most frequent neoplasms were breast carcinomas (14 cases/14.9%), thyroid (7 cases/7.4%), lung and kidney (3 cases/3.1%), melanomas (5 cases/5.3%). The most frequent precancerous condition was Barrett's esophagus (7 cases/63.3%). Regarding the antibody profile, 5 (4.8%) patients were positive for anti-RNAP3 and only 2 (1.9%) of these patients presented a malignant neoplasm, breast cancer in both cases. In 30 cases (28.6%) these neoplastic/precancerous conditions had arisen in the close period ($\pm$ 36 months) at the SSc diagnosis and only 3 of them were anti-RNAP3 positive. Among the evaluated risk factors. Only familiarity was significantly associated with the development of neoplasia ($p = 0.003$), confirmed at the multivariate analysis (OR 2.9, IC95% [1.5-5.7]; $p=0.002$).

Conclusion: our study evaluated not only malignant neoplasms, but also benign neoplasms and precancerous conditions and identified familiarity as the only significant risk factor. In our cohort we didn't find any relationship between the presence of anti-RNAP3 antibodies and the development of neoplasms, not even stratifying for the type of neoplasm. However, to better define our data, we should analyze anti-RNAP3 also in the double negative (antiSci70 and ACA) cases, in light of the recent evidence of double antibody positivity, as well as other newly investigated rare autoantibodies, associated with neoplasm in many connective tissue diseases, including SSc.

REFERENCES

- [1] Szekanecz E, et al. (2012) *Autoimmun Rev* 11, 852;
- [2] Shaha AA et al (2017) *J Scleroderma Relat Disord*. 2, 153;
- [3] Van den Hoogen F, et al. (2013) *Ann Rheum Dis* 72, 1747–55.

Disclosure of Interests: Katia Stefanantoni Consultant for: Only 1 scientific advice for Italfarmaco in 2016, Natalia Di Tommaso: None declared, Nicoletta Iannace: None declared, Iliana Sciarra: None declared, Carlotta Angelelli: None declared, Elena Marafioti: None declared, Greta Pellegrino: None declared, massimiliano vasile: None declared, Guido Valesini: None declared, Valeria Ricciari: None declared

DOI: 10.1136/annrheumdis-2019-eular.7801

AB0689

EVALUATION OF CARDIOVASCULAR DETERMINANTS OF DISEASE OUTCOME IN SYSTEMIC SCLEROSIS

Mariann Kalászi¹, Renáta Laczkó², Pál Soltész², Katalin Hodosi¹, Szilvia Szamosi¹, Zoltán Szekanecz¹, ¹Gabriella Szűcs. ¹University of Debrecen, Faculty of Medicine, Department of Rheumatology, Debrecen, Hungary; ²University of Debrecen, Faculty of Medicine, Department of Angiology, Debrecen, Hungary

Background: Systemic sclerosis (SSc) is a systemic autoimmune disease characterized by microvascular abnormalities. Cardiopulmonary and vascular manifestations in SSc are the most important survival factors in the disease.

Objectives: Correlations between different cardiovascular parameters (ejection fraction (EF), diastolic dysfunction, wall motion disturbance, estimated systolic pulmonary arterial pressure (sPAP), flow-mediated vasodilatation, arterial stiffness parameters (augmentation index - Alx, pulse wave velocity - PWV) and disease outcome and death were measured.

Methods: Thirty-six SSc patients were involved who underwent detailed arterial stiffness and vasodilatation examinations in 2007. In our work a 10-year period was analysed till 2017 following the progression of organ manifestations and survival.

Results: During the 10-year follow-up, 13 of the 36 patients died. The average survival time was 26.59 (22.36-37.64) years. Significant correlation was found between the initial Alx and PWV with cardiac wall motion disturbance ($p = 0.018$ and $p = 0.016$), Alx with restrictive ventilation dysfunction ($p = 0.029$) and PWV with obstructive ventilation dysfunction ($p = 0.015$). During the 10-year period, the occurrence of diastolic dysfunction was significantly increased ($p = 0.0016$), the incidence of arrhythmia did not change significantly. A significant risk factor for survival has been the decrease in EF ($p = 0.011$), where 1% reduction in EF was associated with 1.9% increase in mortality and 1 mmHg increase in sPAP involved 13% increase in mortality.

Conclusion: Based on our findings vascular stiffness parameters can be the predictors not only of the cardiovascular mortality but pulmonary manifestations with restrictive ventilation disturbances also in SSc.

Disclosure of Interests: Mariann Kalászi: None declared, Renáta Laczkó: None declared, Pál Soltész: None declared, Katalin Hodosi: None declared, Szilvia Szamosi Speakers bureau: Roche, Zoltán Szekanecz Grant/research support from: Pfizer, UCB, Consultant for: Pfizer, Abbvie, Roche, Sanofi, Lilly, Novartis, Speakers bureau: Pfizer, Abbvie, Roche, Sanofi, Lilly, Novartis, Gabriella Szűcs Speakers bureau: Actelion, Roche, Sager

DOI: 10.1136/annrheumdis-2019-eular.2454

AB0690

USE OF MYCOPHENOLATE IN SYSTEMIC SCLEROSIS. CASE SERIES

Jose Luis TANDAIPAN JAIME¹, Elena Riera Alonso¹, Alba Alvarez-Abella², Mireia Castillo Vilella³, Georgina Salvador Alarcon¹, Manel Pujol¹, Silvia Martínez Pardo¹, Rheumatology. ¹Hospital Universitari Mutua de Terrassa, Rheumatology, Terrassa, Spain; ²Hospital Universitari Mutua de Terrassa, Dermatology, Terrassa, Spain; ³Hospital Universitari Sagrat Cor, Rheumatology, Barcelona, Spain

Background: At present, there are not specific targets to treat or prevent Systemic Sclerosis (SSc), but there are some to reduce the impact of its associated complications. Although mycophenolate (MP) is not recommended in latest EULAR SSc guidelines to treat cutaneous and pulmonary manifestations, its efficacy is known, based on observational studies and the Scleroderma lung study II.

Objectives: To describe our center's experience in treating SSc patients with MP.

Methods: Descriptive series of SSc patients treated with MP from November 2017 to December 2018. Demographic, clinical, analytical, spirometric, radiological (HR-CT) and modified Rodnan skin score (mRSS) data were collected.

Results: Case 1: woman diagnosed at 42 years old with diffuse SSc, having positive anti-topoisomerase-I antibody (ATA), telangiectasias, pitting scars, scleroderma and Non-specific Interstitial Pneumonia (NSIP) without significant alterations in spirometry. One year after diagnosis, as a result of skin worsening (mRSS 21), we started MP in association with prednisone (mean dose 5 mg. a day). After treatment for 14 months, she showed significant improvement (mRSS 9) without spirometric changes.

Case 2: woman diagnosed at 30 years old with diffuse SSc, having positive ATA, pitting scars, gastroesophageal reflux disease (GERD) and scleroderma. This same year, we started MP due to skin involvement (mRSS 14), improving significantly (mRSS 9) after 14 months of treatment.

Case 3: woman diagnosed at 35 years old with diffuse SSc, having positive anti-RNA polymerase-III (ARA), pitting scars, telangiectasias, calcinosis, myopathy and scleroderma. 40 months after diagnosis, MP and prednisone (mean dose 5mg. a day) were started to treat skin (mRSS 19) and muscle (confirmed by biopsy) involvement. Both showed significant improvement after 8 months of treatment, with mRSS 13, myopathy symptoms resolution and creatine kinase (CK) normalization.

Case 4: a woman diagnosed at 35 years of age with limited SSc, having positive anti-Ro52, telangiectasias, skin involvement (mRSS 14) and NSIP with non-assessable spirometry. Clinical respiratory improvement was shown after just 1 month of treatment, without mRSS changes.

Case 5: woman diagnosed at 54 years old with diffuse SSc, having positive ATA, hands edema, scleroderma (mRSS 11), GERD and NSIP (FVC 56%, FEV1 64%, non-assessable DLCO). After 25 months of disease